Identifying high performing research sites is widely recognized as one of the most cumbersome and time consuming activities in clinical trial startup. The startup phase directly determines how quickly a study can enroll subjects, whether enrollment goals will be met, and whether the data collected will be of sufficient quality to support regulatory submission. Delays or poor site selection at this stage translate into lost time, higher costs, and compromised study outcomes for sponsors and contract research organizations alike.
Managing clinical studies has traditionally relied on a fragmented mix of tools including phone, fax, email, and Excel spreadsheets. The investigator initiation process, submission of new investigator packages, and feasibility assessments are all labor intensive by nature, and the field has long recognized the need for improvement. Understanding the strengths and limitations of each available approach to site identification is an essential starting point for any clinical trial startup strategy.
Internal Databases in Clinical Trial Startup
Sponsors and CROs typically maintain internal databases of sites they have worked with previously. These databases offer immediate accessibility, pre populated site information, and the advantage of established long term relationships with investigators who are already familiar with sponsor expectations and processes.
The limitation is that internal databases require continuous maintenance to remain accurate and useful. As databases grow larger, keeping them current becomes progressively more resource intensive. For new therapeutic areas or indications where the sponsor has limited prior experience, static internal databases are often insufficient, forcing the clinical trial startup team to look outside their existing network and identify sites they have never worked with before.
Key Opinion Leaders and Referrals in Clinical Trial Startup
Referrals from key opinion leaders, or KOLs, represent another commonly used approach. KOLs are recognized experts with firsthand experience in a specific therapeutic indication, and their recommendations carry weight precisely because they are grounded in direct knowledge of the research landscape. Their insights can surface high performing sites that might not appear in any directory or database.
The practical challenges are that KOLs can be difficult to reach, may not personally conduct clinical research, and are not always available on the timeline that clinical trial startup demands. This method works best when sponsor teams have pre existing relationships with relevant KOLs in the target indication.
CROs and SMOs as Clinical Trial Startup Partners
Contract research organizations and site management organizations offer a more structured option for site identification. CROs manage and continuously update their own site networks, and SMOs maintain investigator networks within specific indications, providing both database access and operational support for the startup process.
This approach offers the significant advantage of delegating site identification work to organizations whose core competency it is. The tradeoff is cost: CRO and SMO fees represent a meaningful investment, and these organizations do not always accommodate sponsor preselected sites outside their existing networks. For sponsors with tight budgets or strong preferences for specific investigators, this can be a limiting factor.
Directories and Their Role in Clinical Trial Startup
Online directories allow sponsors to cast a wide net during site feasibility, providing broader lists of potential sites than any single internal database could offer. Some directories are available at no cost, making them an accessible starting point for teams with limited resources.
The limitation is quality control. It is often difficult to verify how current a given directory is, and identifying sites through a directory still requires contacting each one individually to assess feasibility, a time consuming process that can slow clinical trial startup considerably.
Regardless of which combination of methods a sponsor uses, the quality of the site identification process ultimately determines the quality of the study. Delegating this function to professionals whose careers are focused on clinical trial startup and site management remains one of the most effective ways to accelerate enrollment and protect data integrity.
To learn more about how FOMAT operates as an embedded research organization supporting sponsors and CROs, visit the FOMAT website. For more resources on clinical research best practices, visit the FOMAT blog.
For additional industry perspectives, see resources at FDA.gov.